Berkshire Hathaway Inc. vs Gilead Sciences, Inc.: Strategic Comparison

This in-depth comparison examines Berkshire Hathaway Inc. and Gilead Sciences, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Berkshire Hathaway Inc. on its own, evaluating Gilead Sciences, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Berkshire Hathaway Inc. and Gilead Sciences, Inc. is widest.

On the headline numbers, Berkshire Hathaway Inc. reports annual revenue of $371.4B against $29.4B for Gilead Sciences, Inc., while their respective market capitalizations stand at $1.05T and $135.0B. Berkshire Hathaway Inc. is headquartered in United States and Gilead Sciences, Inc. operates from United States, and those different home markets shape how each company competes.

Berkshire Hathaway Inc.: Few financial facts stop a room quite like this one: a single share of Berkshire Hathaway Class A stock costs more than most Americans earn in a decade. That one data point encapsulates something profound about the institution Berkshire Hathaway has become: an anomaly so extreme it defies the normal categories of corporate analysis. What Buffett built over the following six decades is something that defies easy categorization. It owns GEICO, which insures more than 18 million vehicles. It owns BNSF Railway, which hauls freight across 32,500 miles of track through 28 US states. It owns Berkshire Hathaway Energy, with electric utility operations serving millions of customers. Abel, a Canadian-born executive who built Berkshire Hathaway Energy into a multi-hundred-billion-dollar utility powerhouse, brings operational depth that Buffett himself acknowledged he lacked. The question Wall Street has been asking for fifteen years — what happens after Buffett? — is now being answered in real time, and early evidence suggests Berkshire's culture, capital allocation framework, and institutional identity are more durable than the skeptics predicted. Over more than fifty-five years, that argument has been proven correct with mathematical precision. It does not sell a unified service. It does not operate with traditional corporate hierarchies, shared services infrastructure, or centralized procurement. **The Insurance Float Engine** For Berkshire, under Buffett's direction, float became the raw material of empire. No bank offers this arrangement. No bond market replicates it. GEICO has historically been one of the most cost-efficient auto insurers in the United States. Berkshire Hathaway Reinsurance Group handles massive, complex reinsurance transactions. BHE has faced significant headwinds from wildfire liability issues particularly related to its PacifiCorp subsidiary in Oregon, but remains a core component of Berkshire's infrastructure holdings. Apple remains the single largest position, though trimmed from over 900 million shares to approximately 300 million shares by year-end 2024. American Express, Bank of America, Coca-Cola, Chevron, Occidental Petroleum, Kraft Heinz, and Moody's are among the other major positions. **The Capital Allocation Framework** When the equity portfolio generates dividends, that flows to Omaha. When insurance operations generate underwriting profits, that flows to Omaha. **The Decentralized Operating Model** Berkshire's headquarters in Omaha employs roughly 25 people. Its headquarters in Omaha, Nebraska employs a corporate staff of roughly 25 people who oversee approximately 90 operating subsidiaries employing nearly 396,000 workers across insurance, transportation, energy, manufacturing, retail, and financial services. Its Class A shares trade above $700,000 — a deliberate signal of long-term ownership philosophy. There are no shared services functions, no centralized HR or IT departments, no corporate acquisition integration teams. No single revenue stream dominates, and this diversification has historically provided earnings stability through economic cycles that cyclical or single-industry companies cannot match. The management transition has been deliberately gradual, allowing institutional knowledge, relationships, and cultural continuity to transfer without disruption. Berkshire enters the mid-2020s with record operating earnings, unprecedented cash reserves, and a succession framework designed to endure for another generation. Berkshire Hathaway does not compete in conventional terms. The most direct competitive set for Berkshire's holding company model includes other large diversified conglomerates: 3M, Honeywell, and General Electric historically, though GE's protracted unraveling over two decades stands as a cautionary tale about conglomerate excess rather than a competitive threat to Berkshire. In the private equity world, firms like Blackstone, KKR, and Apollo compete for some of the same acquisition targets, but with structurally different objectives — they manage funds with defined lives and return-of-capital mandates, meaning they must eventually sell their acquisitions. BNSF has faced criticism for service quality and Union Pacific has made gains in certain commodity segments. When Buffett held Coca-Cola stock for over thirty years, he was not subject to the quarterly performance pressure that forces most institutional managers to trade around their convictions. Warren Buffett has repeatedly described his desire to make 'elephant-sized' acquisitions — deals large enough to meaningfully impact Berkshire's earnings. **Wildfire Liability and the BHE Overhang** Berkshire Hathaway Energy's PacifiCorp subsidiary faces billions of dollars in potential liability from Oregon and California wildfires. **The Succession and Cultural Continuity Question** **GEICO's Competitive Position** **Interest Rate and Valuation Sensitivity** Berkshire's enormous equity portfolio — heavily weighted toward financial stocks and consumer brands — creates meaningful exposure to equity market valuations. **The Reputation Premium** The Nebraska Furniture Mart's Rose Blumkin, See's Candies, and dozens of other foundational acquisitions came to Berkshire through this channel. This eliminates enormous overhead costs while preserving entrepreneurial cultures. **Capital Deployment Patience** These stakes provide exposure to diversified commodity and industrial value chains with valuation characteristics reminiscent of early Berkshire acquisitions. Share repurchases, while decelerated in 2024, remain a capital return tool when the stock trades below Buffett and Abel's estimate of intrinsic value. Abel has demonstrated exceptional capital allocation skills through his stewardship of Berkshire Hathaway Energy, transforming it from a regional Iowa utility into a multi-state energy empire. A major market dislocation — a recession, a financial crisis, or a sector-specific collapse — could create the acquisition opportunity that Berkshire has been unable to find. Buffett has noted that Berkshire could deploy $50-100 billion in a suitable acquisition without stress. Insurance, energy infrastructure, and consumer staples remain the most natural areas for elephant-sized deals. Chace was a protégé of Samuel Slater, the British-born industrialist who transplanted the industrial revolution's textile machinery to America and established the foundations of New England's textile industry. By the early 1960s, Berkshire Hathaway was a declining industrial enterprise. By the time the mills required their periodic machinery upgrades, Buffett observed, management would tender for shares at slight premiums to the trading price, then after the tender closed, the stock would fall back below the tender price. Then something went wrong — or rather, something went wrong that ultimately led to everything going right. In 1964, Berkshire's president Seabury Stanton offered to buy out Buffett's shares at $11.50 per share. Buffett agreed verbally. But when the formal tender arrived, Stanton had changed the offer to $11.375 per share — an eighth of a dollar less than the oral agreement. 'It was a terrible mistake,' he would later say, repeatedly and publicly. This was not a dramatic transaction at the time. But it introduced Warren Buffett to the concept that would define Berkshire's model: insurance float. The textile operations were finally closed in 1985, twenty years after Buffett's takeover. The mills had been drained of cash, which had been deployed into far more productive enterprises.

Gilead Sciences, Inc.: The financial mechanics of this diversified model are exceptionally complex, requiring the simultaneous management of a high-volume, high-margin small molecule manufacturing network for HIV therapies, and a highly customized, logistically complex autologous cell therapy supply chain for oncology. This margin structure is vastly superior to the 15-20% margins typical of generic manufacturers, but it requires massive upfront capital deployment in specialized manufacturing facilities and clinical development programs. The revenue streams are heavily concentrated in a few massive blockbuster franchises. The antibody-drug conjugate (ADC) model used by Trodelvy involves attaching a highly potent cytotoxic payload, specifically SN-38, to a monoclonal antibody that targets the Trop-2 receptor expressed on the surface of cancer cells. The CAR-T cell therapy model used by Yescarta represents a fundamentally different economic model, requiring the extraction of a patient's own T cells, their genetic modification using a lentiviral vector to express a chimeric antigen receptor, and their reinfusion into the patient after a complex manufacturing process that takes approximately three weeks. The commercial infrastructure required to support this model is highly specialized. Gilead employs a sales force of thousands of highly trained scientific liaisons who engage directly with infectious disease specialists, oncologists, and hematologists, providing complex clinical data rather than simple product pitches. In the oncology space, the competitive dynamics are far more complex. Companies like Regeneron in oncology and Vertex in rare diseases operate with lower overhead and higher R&D efficiency, allowing them to bring novel modalities to market faster than a diversified giant like Gilead. This high gross margin is characteristic of the innovative biopharmaceutical industry and reflects the relatively low marginal cost of manufacturing small molecule drugs and biologics once the initial capital-intensive manufacturing facilities have been built and the regulatory approvals have been obtained. The discontinuation of magrolimab in 2023 following Phase III trial failures in myelodysplastic syndromes resulted in a significant write-down and highlighted the unforgiving nature of late-stage clinical development.

Berkshire Hathaway Inc. and Gilead Sciences, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Berkshire Hathaway Inc. and Gilead Sciences, Inc..

Berkshire Hathaway Inc. business model: All of these elements feed into the central function: capital allocation. Honestly, Berkshire generates revenue from an extraordinarily diverse set of sources: insurance premiums, freight revenues, electricity sales, manufactured goods, wholesale distribution, restaurant royalties, aircraft chartering, and dozens of other business lines. Berkshire never sells, and that permanence is itself a competitive differentiator that private equity cannot match. The real competitive battle is for shipper relationships, pricing discipline, and service reliability. But Berkshire's competitive position here is unique: it does not manage outside capital, has no redemption pressures, pays no management fees, and can hold positions for decades without client reporting pressure. Berkshire Hathaway Energy's contribution to earnings was complicated by wildfire-related reserve charges. GEICO experienced significant underwriting losses in 2022 and faced market share erosion as Progressive Corporation surged ahead using telematics-based pricing that more precisely matched premiums to actual driver risk.

Gilead Sciences, Inc. business model: The financial mechanics of this model are exceptionally lucrative but heavily constrained by the complex pricing dynamics of the US healthcare system and the logistical challenges of manufacturing advanced biologics. This autologous manufacturing model is incredibly expensive and logistically complex, requiring a highly specialized supply chain and dedicated clean room facilities, but it commands premium pricing, with Yescarta listed at approximately $410,000 per treatment, reflecting the curative potential of the therapy in relapsed or refractory large B-cell lymphoma. The pricing power inherent in the innovative pharma model allows Gilead to charge premium list prices in the US market, which accounts for approximately 65% of total global sales. However, this pricing power is heavily distorted by the US pharmacy benefit manager (PBM) system. This strategy of identifying unmet medical needs in complex, chronic diseases and developing targeted therapies to address them is a core component of Gilead's competitive strategy, allowing the company to command premium pricing and achieve high margins despite the intense competitive pressure in the broader virology and oncology markets. The US market remains the most profitable region, contributing approximately 65% of total revenue but an even higher percentage of operating profit due to the significantly higher pricing power for innovative therapies in the United States compared to Europe and Asia. While Gilead's lenacapavir has demonstrated unprecedented efficacy as a twice-yearly injectable for PrEP, the commercial rollout of this asset requires the establishment of a specialized injection infrastructure and faces significant pricing and reimbursement hurdles in the global market. The legal and regulatory battles surrounding the pricing of HIV therapies in the US represent another critical challenge. Gilead has faced intense scrutiny from state attorneys general and federal regulators regarding its pricing strategies and rebate agreements with PBMs, allegations that the company has consistently denied but which have resulted in significant legal fees and reputational damage. The existence of a parallel, low-cost supply chain for HIV pre-exposure prophylaxis, driven by the availability of generic Truvada and the compounding of oral antiretrovirals, has permanently altered patient and payer expectations regarding the pricing of HIV prevention therapies, making it increasingly difficult for Gilead to maintain its premium list prices for Descovy and lenacapavir without facing intense public and political backlash. The company's deep integration with academic medical centers through its clinical trial network creates a feedback loop of real-world data that accelerates regulatory approvals and label expansions, further entrenching its dominance in the therapeutic area. The company must also navigate the complex and evolving pricing and reimbursement landscape, particularly in the US where the implementation of the Inflation Reduction Act is expected to put significant downward pressure on drug prices.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Berkshire Hathaway Inc. stack up against those of Gilead Sciences, Inc..

Berkshire Hathaway Inc. competitive advantage: The conglomerate's financial scale is staggering. It is the structural advantage that made everything else possible. This capital discipline — the willingness to hold enormous cash reserves and wait rather than deploy capital at mediocre returns — is, paradoxically, one of Berkshire's most powerful competitive advantages. The competitive dynamics here are relatively stable — railroads are natural monopolies or duopolies within geographic territories, and the barriers to entry (capital requirements, land, regulatory approvals) are essentially insurmountable. The deepest competitive moat, however, is cultural and reputational, and it manifests most powerfully in acquisition dynamics. This reputational moat took decades to build and would take decades to erode, making it Berkshire's most durable long-term competitive advantage. As Berkshire's scale has grown, its addressable deal universe has shrunk. Additionally, Berkshire's investment in fixed-income instruments is influenced by interest rate cycles, and any sharp normalization in rates in either direction creates portfolio management complexity at the scale Berkshire operates. Berkshire Hathaway's competitive advantages are structural, cultural, and reputational — and they compound over time in ways that create barriers to imitation that no single rival can overcome. **The Float Advantage** This structural advantage has been described by financial academics as the single most important factor in Berkshire's long-term outperformance relative to the S&P 500. **Decentralized Management Scale** No traditional conglomerate has successfully replicated this model at scale. When markets dislocate, Berkshire can act at extraordinary scale and speed. Berkshire's diverse business portfolio creates unusual informational advantages. On the acquisition front, Berkshire is explicitly targeting businesses with durable competitive advantages, predictable earnings, honest management, and prices that make economic sense for a permanent, non-selling owner. Buffett's stated preference remains for 'simple businesses we understand' with returns on equity above 15%, low debt, and sustainable moats. But the structural disadvantage was insurmountable.

Gilead Sciences, Inc. competitive advantage: The execution of this strategy requires flawless commercial execution and unprecedented manufacturing scale, capabilities that were severely tested during the rapid scale-up of Yescarta production and the global deployment of Veklury. This franchise relies on the continuous optimization of single-tablet regimens that combine multiple antiretroviral agents, such as bictegravir, emtricitabine, and tenofovir alafenamide, into a single pill that patients can take once daily with a high genetic barrier to resistance. This targeted delivery mechanism allows for the destruction of tumor cells while minimizing systemic toxicity, a clinical advantage that has driven rapid adoption in third-line triple-negative breast cancer and second-line urothelial cancer. The CAR-T market is particularly vicious because patient switching costs are high, and physicians are reluctant to change therapies unless new data demonstrates superior long-term outcomes and a better safety profile. This dynamic creates a constant tension between internal R&D productivity and external capital deployment, a balance that CEO John F. Milligan has managed by strictly prioritizing acquisitions that offer late-stage, de-risked assets in areas where Gilead already has commercial scale. The successful completion of these trials has established lenacapavir as a significant prevention agent, a competitive advantage that is extremely difficult for new entrants to replicate without conducting their own multi-year, multi-billion dollar outcomes trials. The scale-up of Yescarta production requires the continuous addition of new clean room suites and the optimization of the lentiviral vector supply chain, a logistical challenge that exposes the company to production delays, regulatory inspections, and raw material shortages. The bictegravir molecule, the integrase strand transfer inhibitor at the core of Biktarvy, is not a simple chemical entity that can be easily reverse-engineered by generic manufacturers; it requires a highly complex synthetic pathway and precise formulation to achieve the optimal pharmacokinetic profile that allows for once-daily dosing with a high genetic barrier to resistance. This specific molecular architecture is protected by a dense thicket of composition-of-matter, formulation, and method-of-use patents that do not expire until the 2030s, creating a legal barrier to entry that is virtually impossible to close quickly. The clinical data package surrounding Biktarvy, encompassing over 100,000 patient-years of exposure across the GS-US-380-1474, GS-US-380-1489, and GS-US-380-4030 trial programs, represents a competitive advantage that is rooted in deep scientific expertise, massive capital barriers, and regulatory exclusivity. The transition to lenacapavir, a first-in-class capsid inhibitor, further solidifies this competitive advantage. The manufacturing moat for the company's CAR-T therapies is equally formidable. Gilead operates the largest autologous CAR-T manufacturing network in the world, located in El Segundo, California, and Lingan, Belgium, which are specifically designed to handle the complex biological processes required to produce Yescarta at commercial scale. The sheer cost and regulatory complexity of building and operating these facilities deter all but the most well-capitalized competitors from attempting to enter the CAR-T space, giving Gilead a significant cost and scale advantage that will be difficult to replicate. This regulatory expertise, combined with its manufacturing scale and clinical data dominance, creates a comprehensive competitive advantage that positions Gilead as the undisputed leader in the rapidly evolving field of oncology cell therapies. The commercial infrastructure required to support this advantage is equally specialized. The early data has shown promising tumor response rates and safety profiles, suggesting that Gilead could potentially launch the first next-generation ADC in these indications by 2028, establishing another first-mover advantage in a completely new therapeutic area and creating a multi-billion dollar revenue stream that would significantly diversify the company's oncology portfolio. The successful commercialization of these advanced modalities will require the development of new manufacturing capabilities and commercial infrastructure, as allogeneic therapies are typically administered as a single dose and require complex, large-scale manufacturing processes. Gilead has established a dedicated AI and data science hub in Foster City, which is focused on developing machine learning algorithms to analyze large-scale biological datasets, identify novel drug targets, and optimize the design of clinical trials.

Future prospects matter as much as current results. The growth strategies below explain how Berkshire Hathaway Inc. and Gilead Sciences, Inc. each plan to expand from here.

Berkshire Hathaway Inc. growth strategy: It was purchased by a young Omaha-based partnership manager named Warren Buffett not as a foundation for empire-building but, by his own repeated admission, as a mistake — a 'cigar butt' investment he grabbed because the price was cheap, even though the underlying business was fundamentally impaired. Berkshire Hathaway is simultaneously an insurance company, a railroad operator, a utility provider, a manufacturer, a retailer, a financial services firm, and one of the world's largest equity investment portfolios. The company's equity investment portfolio, though reduced from peak Apple concentration, still carries tens of billions in positions across financial services, consumer staples, and energy. This radical decentralization is not a management flaw but a deliberate philosophy: Berkshire acquires exceptional businesses run by exceptional managers and then, in Buffett's words, gets out of their way. The company also manages one of the largest equity investment portfolios in the world, with significant positions in Apple, American Express, Bank of America, and Coca-Cola. Instead, Berkshire Hathaway is, at its most fundamental level, a capital allocation machine — an entity whose core competency is identifying excellent businesses, acquiring them at reasonable prices, retaining exceptional managers, and then redeploying the cash those businesses generate into new investments over extremely long time horizons. The time gap between premium collection and claim payment generates a pool of investable cash called float. For most insurance companies, this float is a liability — an obligation that must be managed carefully and invested conservatively. This is money that does not belong to Berkshire in the traditional sense — it will eventually be paid out in claims — but in the meantime, Berkshire gets to invest it. **The Equity Investment Portfolio** When Berkshire's operating businesses generate more cash than they need for maintenance and organic growth, that cash flows to Omaha. And then Berkshire decides where to deploy it next — acquisitions, equity investments, stock buybacks, or Treasury bills to wait for the next opportunity. This radical decentralization eliminates corporate overhead, preserves the entrepreneurial cultures that made acquired companies excellent in the first place, and allows Berkshire to own vastly more businesses than any traditional conglomerate could manage. The model works because Berkshire acquires businesses with proven management already in place, and then trusts those managers rather than imposing corporate bureaucracy on them. The company's investment portfolio holds hundreds of billions in publicly traded equities. This structure was designed by Warren Buffett to preserve the entrepreneurial cultures that made acquired businesses excellent while eliminating the bureaucratic overhead that typically expands with corporate scale. The irony is, the competitive response under Todd Combs, who took operational control of GEICO, has involved significant technology investment, a reduction in advertising spend in favor of profitability, and aggressive rate increases to restore underwriting margins. But both railroads face the longer-term structural question of whether coal traffic decline will be offset by intermodal and agricultural growth. BHE has historically differentiated through aggressive investment in renewable energy — it was among the first US utilities to commit to zero-carbon electricity generation across its service territories. However, the wildfire liability crisis related to PacifiCorp has created financial uncertainty and diverted management attention from growth investments, potentially allowing better-capitalized competitors to advance renewable development programs more aggressively. This operating earnings figure reflects the combined pre-tax earnings of all Berkshire's subsidiaries plus investment income, minus corporate expenses and taxes. Berkshire's book value per share grew to approximately $459,000 per Class A equivalent share, and the stock's price-to-book ratio expanded as investor confidence in the post-Buffett transition grew. Berkshire's brand is inseparable from Warren Buffett in the minds of most investors. When that float is generated at zero cost or below (underwriting profit), Berkshire effectively receives free financing to invest across its portfolio. Berkshire's reputation as a permanent, hands-off acquirer commands a premium in deal negotiations. Business owners who have spent decades building their companies — and care deeply about what happens to their employees, their culture, and their customers after they sell — often choose Berkshire over private equity buyers who offer higher prices but come with integration plans, cost-cutting mandates, and eventual re-sale. This was demonstrated during the 2008 financial crisis (investments in Goldman Sachs and GE on highly favorable terms) and repeatedly in subsequent market dislocations. Management insights from BNSF's freight volumes, McLane's distribution data, and GEICO's customer demographics collectively provide Buffett and Abel with a real-time economic dashboard that few investors or operators can match. Berkshire Hathaway's growth strategy, as articulated in Buffett's annual letters and operationalized under Greg Abel's day-to-day leadership, centers on disciplined capital allocation across four channels: wholly-owned business acquisitions, equity investment portfolio additions, organic investment within existing subsidiaries, and opportunistic share repurchases. Within existing businesses, Berkshire is pursuing significant capital investment programs. BNSF plans to invest billions annually in track infrastructure, technology, and operational efficiency improvements. Berkshire Hathaway Energy is executing a multi-decade transition toward renewable generation, with wind, solar, and transmission infrastructure investments running into the tens of billions. These organic investment channels allow Berkshire to deploy substantial capital into businesses it already understands deeply. Japan has emerged as an interesting international growth vector. As intrinsic value grows with operating earnings, the buyback calculation will periodically favor repurchases over cash accumulation. Berkshire Hathaway Energy's clean energy transition represents one of the most significant growth opportunities: the company has committed to massive renewable energy investment and could accelerate that investment as wildfire liability clarity emerges. Enter Warren Edward Buffett, a 32-year-old investor from Omaha who had learned the craft of value investing under Benjamin Graham at Columbia Business School and subsequently managed a highly successful investment partnership in Omaha. Buffett's partnership had already accumulated modest profits in various industries when, in 1962, he noticed that Berkshire Hathaway's stock was trading at approximately $7.50 per share while the company's working capital alone was worth considerably more. It was a pattern Buffett recognized from Graham's 'net-net' investment framework — buying a dollar of value for significantly less than a dollar of price. By 1965, Buffett's partnership controlled Berkshire Hathaway and Buffett replaced Stanton as president. The irony was immediately apparent: Buffett had acquired control of a business he knew was fundamentally impaired. The textile mills continued to require capital investment that never earned adequate returns. Buffett tried for nearly two decades to make the textile operation viable, investing in new machinery, exploring different product lines, and working with management to reduce costs. National Indemnity's float — the gap between premiums collected and claims paid — gave Buffett investable capital at a cost that approached zero when underwriting was profitable. He recognized immediately that this was the ideal financing structure for his investment approach: patient, permanent capital with no redemption risk and potentially negative carrying costs. He would spend the next five decades building the world's largest collection of insurance operations around this insight. The Berkshire Hathaway name survived as the holding company's brand — a perpetual reminder, Buffett has said, of the 'penalty' he paid for an emotional investment decision in 1964.

Gilead Sciences, Inc. growth strategy: This narrative of scientific ambition, strategic risk, and financial discipline defines the modern Gilead Sciences, an organization that has successfully used the cash flows from curative hepatitis C therapies to build a diversified biopharmaceutical enterprise capable of competing in the most complex therapeutic areas known to modern medicine. The market has rewarded this diversification strategy with a stable valuation multiple, recognizing that a company with multiple late-stage pipeline assets and a strong commercial infrastructure is worth significantly more than a pure-play virology company facing a patent cliff. To mitigate the risks associated with the impending patent expirations for its core HIV assets in the 2030s, the business model incorporates aggressive inorganic growth and massive organic capital deployment. The company uses its substantial free cash flow to acquire clinical-stage biotechnology companies that have already de-risked their lead assets through Phase II trials. The ultimate goal of the business model is to achieve a sustainable compound annual growth rate (CAGR) of 5-8% at constant currency through 2030, a target that requires the successful launch of next-generation assets like lenacapavir for HIV prevention and treatment, and the continuous expansion of the oncology portfolio into earlier lines of therapy. This logistical constraint creates a massive barrier to entry for competitors, as it requires the establishment of a decentralized network of specialized manufacturing facilities and cold-chain distribution partners, a capital-intensive infrastructure that Gilead has spent the last decade building through the integration of Kite Pharma and subsequent organic investments. For Biktarvy, the company has continuously expanded the label to include new patient populations, such as those with renal impairment or those switching from other regimens, while also conducting long-term safety studies to maintain physician confidence. The company has consistently returned over 50% of its free cash flow to shareholders through a progressive dividend policy and an aggressive share buyback program, a strategy that has supported the stock price during the transition period between the hepatitis C cash windfall and the scaling of the oncology portfolio. The company's research centers in Foster City, El Segundo, and Cambridge focus on advanced areas such as capsid inhibition, targeted protein degradation, and next-generation cell therapies. Gilead's Trodelvy, an ADC targeting the Trop-2 receptor, is locked in a fierce battle with AstraZeneca's Enhertu, a HER2-targeting ADC that has demonstrated superior efficacy in certain breast cancer subtypes and is rapidly expanding into earlier lines of therapy. Gilead's response has been to pivot its oncology portfolio toward next-generation ADCs and bispecific antibodies, areas where it has a distinct technological lead through its internal discovery engine and external partnerships. The success of Trodelvy in expanding into first-line settings and combination regimens has forced competitors like Pfizer and Daiichi Sankyo to accelerate their own Trop-2 targeting programs, but Gilead's head start in clinical data and commercial scale provides a significant buffer. Gilead's competitive strategy in this space relies on continuous lifecycle management, launching new indications, expanding into earlier lines of therapy, and developing next-generation CAR-T constructs with enhanced persistence and reduced toxicity. The most significant competitive threat, however, comes from the rise of specialized biotechnology companies that focus exclusively on single therapeutic areas or modalities. To counter this, Gilead has adopted a 'buy and partner' strategy, using its massive balance sheet to acquire clinical-stage biotechs like Immunomedics and Forty Seven, effectively outsourcing the early-stage discovery risk to the private markets and then using its global commercial infrastructure to maximize the value of the assets. Gilead has responded by aggressively expanding its clinical trial program, conducting the PURPOSE 1 and PURPOSE 2 trials to evaluate the impact of lenacapavir on HIV incidence in high-risk populations. Selling, general, and administrative expenses were tightly controlled, growing at a slower rate than revenue, which contributed to the margin expansion. This capital return strategy is designed to support the stock price during the transition period between the Veklury decline and the scaling of the oncology portfolio, signaling management's confidence in the long-term cash generation capabilities of the diversified biopharmaceutical model. The FY2024 financial performance validates the strategic decision to aggressively acquire oncology assets, as the addition of Trodelvy and Yescarta has significantly improved the company's overall revenue diversification and reduced its reliance on the HIV franchise. This substantial R&D investment is critical for maintaining the company's competitive position and driving future growth, and it is allocated across a diverse portfolio of early-stage discovery programs, Phase I and II clinical trials, and large-scale Phase III registrational studies like the PURPOSE 1 and PURPOSE 2 trials. Selling, general, and administrative (SG&A) expenses were $8.5 billion, or 29.8% of net sales, reflecting the significant commercial investment required to launch and support the company's growing portfolio of oncology therapies and navigate the complex PBM rebate landscape in the US. The company must also manage the operational complexity of a massively expanded manufacturing footprint. While the initial rounds of negotiation targeted older, high-expenditure drugs, the political momentum to include newer, high-cost oncology and virology therapies in future negotiations is growing rapidly, threatening to compress the 82% gross margin that currently defines the company's financial profile. The company's extensive experience in navigating the complex regulatory landscape for cell therapies, which involves coordination between multiple government agencies including the FDA, the EMA, and various national competent authorities, provides it with a deep institutional knowledge base that accelerates the development and commercialization of new cell therapy assets. Gilead has invested billions of dollars in developing the Kite Pharma commercial network, which employs thousands of highly specialized cell therapy liaisons who manage the complex logistics of patient identification, apheresis, manufacturing, and reinfusion. Gilead Sciences, Inc.'s growth strategy is built on three specific, named initiatives with clear financial targets: the acceleration of long-acting HIV prevention launches, the aggressive expansion of the oncology portfolio through bolt-on acquisitions and internal pipeline advancement, and the lifecycle management of key HIV treatment franchises. The company has committed to launching at least five new molecular entities or major label expansions between 2024 and 2030, a pipeline that includes potential blockbusters in HIV prevention, oncology, and inflammatory diseases. The HIV prevention initiative is the cornerstone of this strategy, with the company investing heavily in clinical trials and manufacturing capacity to launch lenacapavir for PrEP and expand its indication to broader patient populations. The oncology growth strategy focuses on using the Trodelvy and Yescarta platforms to establish Gilead as a leader in solid tumors and hematologic malignancies. The company is advancing next-generation ADCs and bispecific antibodies for lung, colorectal, and pancreatic cancers, as well as expanding the indication for Yescarta into earlier lines of therapy and new patient populations. The HIV treatment lifecycle management strategy aims to extend the commercial life of Biktarvy by launching new combination therapies, expanding into new patient populations, and conducting long-term safety studies to maintain physician confidence. By continuously expanding the clinical utility of these assets, Gilead can defend against generic competition and maintain premium pricing in key markets. To fund these initiatives, the company maintains a disciplined capital allocation framework that prioritizes R&D investment and targeted acquisitions over large-scale, transformational mergers. The acquisition of Immunomedics and the partnership with various academic institutions exemplify this approach, providing the company with de-risked, late-stage assets and critical manufacturing capacity that can be integrated into the existing commercial infrastructure to drive immediate revenue growth. The execution of this growth strategy requires a highly skilled and motivated workforce, and Gilead has invested heavily in talent acquisition and development to ensure that it has the necessary scientific and commercial expertise to succeed. Gilead has also implemented a comprehensive training and development program for its employees, focusing on building the skills and capabilities required to succeed in the rapidly evolving biopharmaceutical industry. The company's culture of innovation and collaboration is a key enabler of its growth strategy, fostering an environment where employees are encouraged to think creatively, take calculated risks, and work together to solve complex scientific and commercial challenges. The growth strategy also includes a strong focus on sustainability and corporate social responsibility, recognizing that the long-term success of the company is inextricably linked to the health and well-being of the communities in which it operates. Gilead has committed to achieving net zero greenhouse gas emissions across its value chain by 2040, and has implemented a comprehensive environmental, social, and governance (ESG) program that focuses on reducing its environmental footprint, promoting diversity and inclusion, and ensuring access to healthcare for underserved populations, particularly in the global HIV response. The company's ESG initiatives are integrated into its overall business strategy, and its performance against these goals is regularly monitored and reported to stakeholders. The successful execution of Gilead's growth strategy will require the company to navigate a complex and dynamic external environment, characterized by rapid technological change, intense competition, and evolving regulatory and pricing pressures. However, the company's strong scientific heritage, strong pipeline, and disciplined capital allocation strategy provide a solid foundation for future growth, and its commitment to innovation and patient-centricity positions it well to deliver on its strategic objectives and create significant value for all stakeholders. The company projects a 5-8% constant currency sales CAGR from 2024 to 2030, a growth rate that relies heavily on the successful commercial launch of next-generation pipeline assets currently in Phase III trials. In the cell therapy space, the integration of the internal pipeline and external partnerships is expected to drive significant revenue growth in multiple myeloma and solid tumors, therapeutic areas where Gilead now holds a strong position with its next-generation CAR-T constructs. Gilead has partnered with leading AI companies to identify novel biological targets and predict patient responses to therapy, a strategy that could significantly reduce the time and cost required to bring new drugs to market. In addition to ADCs, Gilead is heavily invested in the development of next-generation cell therapies, including allogeneic CAR-T and natural killer (NK) cell therapies, modalities that have the potential to provide off-the-shelf treatments for a wide variety of hematologic malignancies and solid tumors. The company's pipeline includes several allogeneic programs developed through its internal research and external partnerships, as well as a strong portfolio of in vivo CAR-T therapies that aim to eliminate the need for ex vivo cell manufacturing. Gilead has invested heavily in its cell therapy manufacturing facilities in California and Belgium, and has established a dedicated commercial team to support the launch of these complex therapies. The company is also exploring the use of digital biomarkers and wearable devices to collect real-time patient data during clinical trials, which could provide more sensitive and objective measures of drug efficacy and accelerate the regulatory approval process. The successful implementation of these digital health initiatives has the potential to significantly improve the productivity of the company's R&D organization and reduce the attrition rate of clinical candidates, ultimately leading to the faster and more efficient development of new medicines. The company faces intense competition in all of its key therapeutic areas, and the failure of any of its late-stage pipeline assets could have a material adverse impact on its financial performance and growth trajectory. Despite these challenges, Gilead's strong portfolio of innovative medicines, strong pipeline, and disciplined capital allocation strategy position it well to deliver sustained long-term growth and create significant value for its shareholders. However, the true breakthrough occurred in the late 1990s when Gilead acquired the rights to a novel nucleotide analog platform from a small biotechnology company, a move that would eventually lead to the development of Viread (tenofovir disoproxil fumarate), the first once-daily nucleotide reverse transcriptase inhibitor for HIV. These acquisitions fundamentally rewired the company's DNA, shifting its focus from a pure-play virology company to a diversified biopharmaceutical enterprise with significant presence in oncology and inflammatory diseases. This narrative of scientific ambition, strategic risk, and financial discipline defines the modern Gilead Sciences, an organization that has successfully used the cash flows from curative hepatitis C therapies to build a diversified biopharmaceutical enterprise capable of competing in the most complex therapeutic areas known to modern medicine.

A closer look at the financial trajectory of Berkshire Hathaway Inc. and Gilead Sciences, Inc. rounds out the comparison.

Berkshire Hathaway Inc.: In fiscal year FY2025, Berkshire reported total revenues of approximately $371.4B, making it consistently one of the top five companies in the United States by revenue. Its cash and Treasury bill holdings reached a record $334 billion by the end of 2024 — a war chest so large it amounts to more than the annual GDP of many sovereign nations. In FY2025, Berkshire reported revenues of approximately $371.4B and net earnings of roughly $88.4 billion, with an extraordinary cash reserve of $334 billion. With approximately 396,000 employees across its subsidiaries and a market capitalization exceeding $1 trillion as of 2025, Berkshire Hathaway represents the ultimate expression of long-term, value-based investing philosophy translated into institutional form. As of year-end 2024, Berkshire's insurance float stood at approximately $174 billion. This is the extraordinary achievement: Berkshire is effectively paid to hold $174 billion in investable capital. The problem is, GEICO, acquired fully in 1996 for approximately $2.3 billion, serves as the retail insurance flagship — insuring automobiles for more than 18 million policyholders through direct marketing that eliminates agent commissions. General Re, acquired in 1998 for approximately $22 billion in stock, provides global property and casualty and life/health reinsurance. Together, these entities generate premium revenues exceeding $80 billion annually while feeding the float engine. BNSF Railway, acquired in 2010 for $44 billion (including assumed debt), is one of North America's two largest freight railroads. BNSF generates revenues consistently exceeding $23 billion annually. Berkshire's manufacturing segment includes Precision Castparts (aerospace components, acquired for $37.2 billion in 2016 — Berkshire's largest acquisition), Iscar (metal cutting tools), Marmon (industrial components), CTB (agricultural equipment), Forest River (recreational vehicles), and dozens of other industrial manufacturers. The service and retail segment includes NetJets (fractional aircraft ownership), FlightSafety (pilot training), Berkshire Hathaway Automotive (auto dealerships), and McLane Company (wholesale distribution to convenience stores and restaurants), which alone generates revenues exceeding $60 billion annually through its distribution operations. Consumer brands within the portfolio include GEICO (already noted), See's Candies (acquired 1972 for $25 million, now generating pre-tax earnings of over $150 million annually on revenues around $550 million), Dairy Queen (acquired 1997), Fruit of the Loom, Duracell (batteries), Brooks Running, and Helzberg Diamonds. Berkshire maintains a publicly disclosed equity investment portfolio that as of early 2025 carries a market value in excess of $300 billion, though the actual composition has shifted significantly as Berkshire reduced its Apple position throughout 2024. In FY2025 alone, Berkshire repurchased approximately $2.9 billion of its own stock. It allowed cash to accumulate to a record $334 billion when attractive opportunities weren't available at acceptable prices. Berkshire Hathaway Inc. is a Diversified Holding Company / Financial Services company with $371.4B in FY2025 revenue and 396K employees worldwide. Its insurance float provides $174 billion in essentially free investable capital. The competitive threat that deserves the most serious attention over the next decade is not from a specific company but from structural market change: the shrinking universe of businesses large enough to matter to a $1 trillion company. Total revenues for FY2025 came in at approximately $371.4B, continuing the company's position as one of the highest-revenue corporations in the United States — a rank driven substantially by McLane Company's pass-through distribution revenues and BNSF's freight operations. Net earnings attributable to Berkshire shareholders reached approximately $88.4 billion in FY2025, though Buffett consistently urges investors to focus on operating earnings rather than GAAP net income, which is heavily distorted by unrealized investment gains and losses that must be marked to market under current accounting rules. Operating earnings — the figure Buffett considers the most meaningful measure of Berkshire's economic performance — came in at approximately $47.4 billion for FY2025, a record high. BNSF contributed revenues of approximately $23.4 billion, though earnings were pressured by volume declines in certain commodity segments and ongoing infrastructure investment. The most attention-grabbing figure in Berkshire's 2024 financials, however, was the cash and short-term Treasury position, which reached $334 billion by year-end — a staggering accumulation that reflected both strong operating cash generation and Buffett's inability to find large acquisitions at prices he considered reasonable. Berkshire repurchased approximately $2.9 billion of its own stock during 2024, a notable deceleration from prior years, consistent with the stock's premium valuation limiting buyback economics. With a market capitalization exceeding $1 trillion and cash reserves of $334 billion as of year-end 2024, a $5 billion acquisition barely registers. Even a $20 billion deal — enormous by any standard — represents less than 2% of Berkshire's market cap. The 2020 Labor Day fires and subsequent litigation have resulted in jury verdicts and settlements that could expose Berkshire to losses in the range of $10 billion to $15 billion according to some estimates, though outcomes remain uncertain. The insurance float of $174 billion as of year-end 2024 represents a cost of capital advantage unavailable to any non-insurance competitor. Berkshire's willingness to hold $334 billion in cash and Treasury bills while waiting for exceptional opportunities — rather than deploying capital at mediocre returns — creates a permanent option value. Berkshire has accumulated significant positions in five major Japanese trading companies — Itochu, Marubeni, Mitsubishi, Mitsui, and Sumitomo — with a combined investment value exceeding $23 billion as of early 2025. Berkshire has repurchased over $75 billion of its own stock since 2018, generating significant per-share value for remaining shareholders. Berkshire Hathaway's future outlook is shaped by three converging forces: the management transition to Greg Abel, the deployment question surrounding its $334 billion cash reserve, and the structural evolution of its largest businesses in a changing economic environment. The $334 billion cash reserve represents both opportunity and pressure. In 1967, for $8.6 million, Berkshire acquired National Indemnity Company and National Fire & Marine Insurance Company, two Omaha-based insurers.

Gilead Sciences, Inc.: The $13.8 billion generated by Biktarvy in FY2024 represents the single most lucrative franchise in the history of virology, a financial monument built on the precise chemical modification of the integrase strand transfer inhibitor class that allows for a once-daily, single-tablet regimen with an exceptionally high genetic barrier to resistance. When Gilead Sciences, Inc. Reported its FY2025 financial results, revealing $29.4B in total product revenue, the numbers confirmed a fundamental truth about the modern biopharmaceutical industry: the company has successfully navigated the catastrophic revenue collapse of the hepatitis C market — a sector that once generated over $30 billion in peak annual sales but has since evaporated due to the curative nature of its own drugs — and replaced it with a highly diversified portfolio spanning HIV, oncology, and inflammatory diseases. The modern corporate entity was founded in 1987 by Michael L. Riordan, a physician and entrepreneur who initially focused on antifungal therapies, but the true strategic inflection point occurred in 2011 when the company executed the $11 billion acquisition of Pharmasset, a move that secured the nucleotide analog platform responsible for Sovaldi and Harvoni. This single transaction generated over $50 billion in cumulative revenue between 2014 and 2018, providing the financial war chest necessary to execute a series of transformational acquisitions that fundamentally rewired the company's DNA. The $11.9 billion purchase of Kite Pharma in 2017 established Gilead as a pioneer in autologous CAR-T cell therapy with Yescarta, while the $21 billion acquisition of Immunomedics in 2020 secured the Sacituzumab govitecan (Trodelvy) platform, creating a dominant position in the antibody-drug conjugate (ADC) space. The company operates with a gross margin of approximately 82%, a figure that reflects the immense pricing power of its patented biologics and small molecules in the US market, where the gross-to-net rebate adjustments for HIV therapies can exceed 40% due to the negotiating leverage of pharmacy benefit managers (PBMs). Despite these massive rebate deductions, the net revenue generated by the HIV franchise provided the company with $10.2 billion in operating income and $6.6 billion in net income during FY2024. This cash generation engine is currently funding a $4.5 billion annual research and development budget, a capital deployment strategy that has resulted in the advancement of lenacapavir, a first-in-class capsid inhibitor that demonstrated 100% efficacy in preventing HIV acquisition in the PURPOSE 1 trial among cisgender women, a clinical result that has the potential to fundamentally alter the global HIV prevention landscape. The introduction of Veklury (remdesivir) in 2020 provided a temporary, massive revenue spike, peaking at $5.5 billion in FY2022, but the subsequent decline of this asset as the pandemic transitioned to an endemic phase left a significant revenue void that the company is now aggressively filling with oncology assets. This concentration of risk in the HIV franchise is being actively mitigated by the expansion of the oncology portfolio, which generated over $3.5 billion in combined sales from Trodelvy, Yescarta, and other oncology assets in FY2024. Gilead Sciences, Inc. is an American multinational biopharmaceutical corporation that reported $29.4B in FY2025 product revenue, operating as a dominant leader in virology and a rapidly scaling oncology powerhouse. Headquartered in Foster City, California, and led by CEO John F. Milligan, the company employs approximately 18,000 people globally and focuses its $4.5 billion annual R&D budget on HIV therapeutics, antibody-drug conjugates, CAR-T cell therapies, and novel antiviral modalities. The company's financial profile is characterized by an 82% gross margin and $6.6 billion in net income, which funds aggressive acquisitions and a strong pipeline of next-generation assets. Key revenue drivers include the HIV franchise, anchored by Biktarvy ($13.8 billion), and the rapidly growing oncology portfolio, led by Trodelvy and Yescarta. Despite facing significant structural challenges, including the impending patent expirations for core HIV assets and the rapid decline of Veklury, Gilead has maintained financial stability through the commercial scaling of its oncology portfolio and the unprecedented clinical efficacy of its next-generation HIV prevention agent, lenacapavir, solidifying its position as a top-tier global biopharmaceutical innovator with a market capitalization of approximately $135 billion. Gilead Sciences, Inc. Generates 100% of its $29.4B FY2025 revenue from the development, manufacturing, and commercialization of patented pharmaceutical products, a business model that relies entirely on scientific differentiation, clinical trial success, and the temporary monopolies granted by global patent offices. The company operates with an 82% gross margin, meaning that for every dollar of net sales, approximately 82 cents flows directly to the bottom line as gross profit, reflecting the immense pricing power of its patented portfolio and the relatively low marginal cost of manufacturing small molecule drugs and biologics at scale. Gilead invested $4.5 billion in research and development during FY2024, a figure that represents approximately 15.8% of total revenue, funding a pipeline of over 50 clinical projects across virology, oncology, and inflammatory diseases. The HIV franchise is the undisputed core of the business, generating $16.5 billion in FY2024 sales, with Biktarvy alone accounting for $13.8 billion. The oncology franchise is the second pillar of the business model, generating $3.5 billion in FY2024 sales, driven by Trodelvy ($1.4 billion) in solid tumors and Yescarta ($1.1 billion) in hematologic malignancies. The $21 billion acquisition of Immunomedics in 2020 brought the Trodelvy ADC platform into the portfolio, while the $4.9 billion acquisition of Forty Seven in 2020 secured the CD47 blocker magrolimab, although the latter asset was ultimately discontinued due to clinical trial failures, highlighting the binary risk inherent in the biopharmaceutical business model. The FY2024 financial results demonstrate that this disciplined approach to capital allocation is generating significant value, as the company has been able to fund its $4.5 billion R&D budget, execute over $5 billion in strategic acquisitions and capital expenditures, and return substantial capital to shareholders, all while maintaining a fortress-like balance sheet with substantial cash reserves and manageable debt levels. Gilead Sciences, Inc. Generated $29.4B in FY2025 net sales, operating as a dominant force in virology and a rapidly scaling oncology powerhouse that commands an 82% gross margin by focusing exclusively on high-margin patented therapeutics. The company's strategic identity was defined through a series of transformational acquisitions, most notably the $11 billion purchase of Pharmasset to secure the hepatitis C platform, and the $21 billion acquisition of Immunomedics to establish a dominant position in ADCs with Trodelvy. This pivot has resulted in a highly diversified portfolio where growth is driven by the HIV franchise, anchored by Biktarvy ($13.8 billion in FY2024 sales), and the rapidly scaling oncology portfolio, led by Trodelvy and Yescarta. With approximately 18,000 employees and a market capitalization of $135 billion, Gilead allocates $4.5 billion annually to R&D, funding a pipeline of over 50 clinical projects and enabling aggressive acquisitions in oncology and cell therapy. Gilead Sciences, Inc. Reported $29.4B in product sales for FY2025, representing a 2% decrease at constant currency compared to FY2023, driven by the rapid decline of Veklury sales which successfully offset the strong growth of the HIV and oncology franchises. The company's operating income surged to $10.2 billion, reflecting a highly efficient cost structure that delivered an 82% gross margin, one of the highest in the global biopharmaceutical industry. Net income reached $6.6 billion, while free cash flow generation remained exceptionally strong at $9.8 billion, providing the financial flexibility to fund a $4.5 billion R&D budget and execute strategic acquisitions. While Veklury sales declined by over 80% due to the transition of COVID-19 to an endemic phase and the expiration of government procurement contracts, the combined sales of Biktarvy ($13.8 billion), Trodelvy ($1.4 billion), and Yescarta ($1.1 billion) demonstrated that the next generation of core franchises is achieving commercial scale and offsetting the legacy revenue void. The company's gross margin remained stable at approximately 82%, reflecting the pricing power of its patented portfolio despite increasing manufacturing costs for complex biologics and cell therapies. The balance sheet remains fortress-like, with substantial cash reserves and manageable debt levels, allowing Gilead to maintain a progressive dividend policy while executing a $2 billion share buyback program authorized in 2024. Net sales of $28.5 billion were composed of $18.5 billion from the US market, $5.2 billion from Europe, $2.8 billion from Asia, and $2.0 billion from the rest of the world. The cost of goods sold (COGS) was $5.1 billion, resulting in a gross profit of $23.4 billion and a gross margin of 82.1%. Research and development expenses totaled $4.5 billion, representing 15.8% of net sales. The operating income of $10.2 billion was achieved after deducting amortization of intangible assets of $1.2 billion and other operating income/expenses of $0.5 billion, resulting in an operating margin of 35.8%. The net income of $6.6 billion was achieved after deducting income taxes of $1.5 billion, resulting in an effective tax rate of 18.5%, which is slightly below the statutory US rate due to the favorable geographic mix of the company's profits and the use of various tax credits and incentives. The strong cash flow generation of $9.8 billion provided the company with the financial flexibility to return $4.2 billion to shareholders through dividends and share buybacks, while also funding $1.5 billion in strategic acquisitions and capital expenditures. The balance sheet at the end of FY2024 showed total assets of $75.3 billion, total liabilities of $45.1 billion, and total equity of $30.2 billion, resulting in a debt-to-equity ratio of 0.85, which is well within the company's target range and provides a strong foundation for future growth and capital allocation initiatives. Biktarvy generated $13.8 billion in FY2024 sales, making it the company's largest single product and the primary engine of corporate cash flow, but the loss of exclusivity will trigger immediate and severe revenue erosion as generic manufacturers and specialized HIV companies introduce lower-cost alternatives. The target is to achieve over $3 billion in annual HIV prevention sales by 2030, a figure that would make this modality one of the company's largest therapeutic franchises. The goal is to achieve peak sales of over $5 billion for the oncology portfolio by 2032. The most critical component of this outlook is the global rollout of lenacapavir for pre-exposure prophylaxis (PrEP), a move that could potentially capture a significant share of the $8 billion annual HIV prevention market and establish a new standard of care for high-risk populations. By 1992, the company was facing a severe cash crunch and was on the brink of bankruptcy, forcing Riordan to execute a desperate initial public offering that raised $86 million and provided the necessary lifeline to continue operations. The $464 million acquisition of Triangle Pharmaceuticals in 2003 secured the rights to emtricitabine, which was combined with tenofovir to create Truvada, the most successful HIV prevention and treatment regimen in history. The subsequent development of Harvoni and Sovaldi for hepatitis C generated over $50 billion in cumulative revenue, transforming Gilead from a niche antiviral player into a global biopharmaceutical powerhouse. The introduction of the hepatitis C curative therapies in 2013 and 2014 triggered a massive cash windfall that allowed the company to execute a series of transformational acquisitions, including the $11.9 billion purchase of Kite Pharma in 2017 and the $21 billion acquisition of Immunomedics in 2020.